Latest Conference Articles

April 17th 2016, 8:50am

AACR Annual Meeting

Single-agent nivolumab demonstrated a robust 5-year overall survival rate of 34% for heavily pretreated patients with metastatic melanoma who had not received prior ipilimumab.

April 16th 2016, 12:06pm

European Lung Cancer Congress

Nicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the benefit of plasma genotyping to predict response to EGFR-targeted therapy in patients with non-small cell lung cancer (NSCLC).

April 16th 2016, 12:04pm

European Lung Cancer Congress

Plasma-based genetic testing can effectively be used to determine whether a tissue biopsy is necessary for EGFR mutation analysis in patients with non–small cell lung cancer.

April 16th 2016, 11:57am

European Lung Cancer Congress

Raffaele Califano, MD, consultant in medical oncology at the Christie NHS Foundation Trust and University Hospital of South Manchester, discuses the potential for immunotherapy in small-cell lung cancer (SCLC).

April 16th 2016, 11:40am

European Lung Cancer Congress

Efficacy and safety remained strong 2 years following treatment with nivolumab for patients with advanced, refractory, squamous non-small–cell lung cancer, with an indication that cytokine levels could predict long-term outcomes.

April 16th 2016, 10:20am

European Lung Cancer Congress

Plasma genotyping can, in most cases, identify T790M-positivity in non-small cell lung cancer, which gives patients the option of receiving the targeted therapy osimertinib without the need for a tumor biopsy, according Geoffrey R. Oxnard, MD.

April 15th 2016, 12:45pm

Community Oncology Conference

Members of the Community Oncology Alliance have issued a call to arms to spur a greater lobbying effort to stop a plan by The Centers for Medicare & Medicare Centers to implement a drug reimbursement change under Medicare Part B.

April 15th 2016, 12:29pm

European Lung Cancer Congress

The first analysis of a trial investigating durvalumab in combination with gefitinib (Iressa) showed encouraging anti-tumor activity and tolerability in patients with non–small cell lung cancer and EGFR mutations that were tyrosine-kinase inhibitor-naïve.

April 15th 2016, 12:12pm

European Lung Cancer Congress

Luis Paz-Ares, MD, PhD, Professor of Medicine at Hospital Universitario 12 de Octubre in Madrid, Spain, discusses a subgroup analysis of patients with EGFR-expressing tumors from the SQUIRE trial, a phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone as first-line treatment for patients with stage IV squamous non-small cell lung cancer (NSCLC).

April 15th 2016, 10:31am

European Lung Cancer Congress

Suresh Ramalingam, MD, professor of Hematology and Medical Oncology at Emory School of Medicine and deputy director of Winship Cancer Institute, discusses first-line treatment with single-agent osimertinib in patients with EGFR-mutated non–small cell lung cancer (NSCLC).

April 15th 2016, 8:18am

European Lung Cancer Congress

Adding necitumumab to conventional chemotherapy improved outcomes in patients with metastatic squamous non–small cell lung cancer in the phase III SQUIRE trial, but the greatest benefit was derived by patients with EGFR-expressing tumors.

April 15th 2016, 6:21am

European Lung Cancer Congress

The first report of results from a phase Ib clinical trial evaluating CRS-207, a live, attenuated, double-deleted Listeria monocytogenes vaccine, in combination with pemetrexed and cisplatin, demonstrated the effectiveness of this approach for patients with malignant pleural mesothelioma.

April 14th 2016, 1:44pm

European Lung Cancer Congress

A new generation of EGFR-targeted TKIs are poised to displace traditional agents as frontline therapies for patients with lung cancer.

April 14th 2016, 1:21pm

European Lung Cancer Congress

John Haanen, MD PhD, epartment of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, discussed the role of PD-L1 as a biomarker in lung cancer.

April 14th 2016, 12:39pm

Community Oncology Conference

Aligning physician compensation to performance can be a dicey matter, as it is difficult to reach a consensus on how to measure physician success. However, a number of oncology practices have been developing systems for doing this and achieving success.

April 14th 2016, 11:33am

European Lung Cancer Congress

First-line treatment with single-agent osimertinib (Tagrisso) induced a response rate of 77% in patients with EGFR-mutated non–small cell lung cancer.

April 14th 2016, 11:21am

European Lung Cancer Congress

Thierry Jahan, MD, professor of medicine at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, discusses CRS-20, a live, attenuated Listeria monocytogenes bacterium which is being investigated with chemotherapy in malignant pleural mesothelioma (MPM).

April 14th 2016, 11:19am

European Lung Cancer Congress

Patients with non-small cell lung cancer who had ceased to respond to EGFR TKI therapy demonstrated a rapid and robust response to the investigational agent BI-1482694 (HM61713).

April 4th 2016, 1:15pm

NCCN Annual Conference

William Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses changes to the NCCN Breast Cancer Guidelines.

April 4th 2016, 12:28pm

NCCN Annual Conference

A new NCCN guideline for the management of vulvar cancer outlines the use of resection, radiation therapy, and chemotherapy based on disease site and stage, recognizing that only 2 randomized treatment trials have been completed.